Physician profile
Andres Roig
NPI 1174700371
$9,130.58
in general payments reported to CMS, 2019-2025
37 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $459 · 2021: $1,302 · 2022: $1,417 · 2023: $2,001 · 2024: $1,584 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,347 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.92 |
| Education | $259.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,388.68 | 2020-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,375.24 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Qol Medical, LLC | $969.60 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $747.00 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $727.35 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $547.61 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $419.31 | 2019-2024 | Linzess |
| Ardelyx, INC. | $376.36 | 2022-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $356.40 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $182.35 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $179.45 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $163.88 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $163.03 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $157.03 | 2022-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $145.39 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $129.99 | 2021-2023 | Talicia |
| Celltrion USA INC. | $127.63 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $104.72 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $101.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $90.86 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $70.15 | 2019-2023 | Injectafer |
| Braintree Laboratories, INC. | $68.07 | 2021-2023 | Sutab |
| Vivus LLC | $67.71 | 2023-2025 | Pancreaze, Qsymia |
| Novo Nordisk INC | $65.14 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $56.68 | 2021-2024 | Dificid |
| Pfizer INC. | $51.95 | 2020-2025 | |
| Pentax of America, INC. | $51.46 | 2021 | |
| Evoke Pharma, INC. | $50.08 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.67 | 2023 | Zeposia |
| Alfasigma USA, INC. | $33.87 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $24.24 | 2024 | Monoferric |
| Janssen Scientific Affairs, LLC | $18.19 | 2021 | |
| Shire North American Group INC | $16.58 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.87 | 2022 | |
| Allergan, INC. | $14.89 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.70 | 2023 | Andexxa |
| Cumberland Pharmaceuticals, INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Roig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.